Drug intelligence / Profile preview

PF-06747143

Development stage: Preclinical
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PF-06747143 is a humanized IgG1 monoclonal antibody that acts as an antagonist of the C-X-C chemokine receptor type 4 (CXCR4). It is developed by Pfizer and has shown potential in treating hematological malignancies by inhibiting CXCL12-mediated signaling pathways. PF-06747143 induces cell death through mechanisms such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). It has been studied in clinical trials for acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL).

Targets

CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on PF-06747143.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06747143.

Explore the full profile